APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Selected research

Market Structure

Global Pneumococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

25 December 2025186 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Read the full market overview

At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.

North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.

This report provides an overview of the global Pneumococcal Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Vaccine Segment by Company

Pfizer

GSK

MSD

Sanofipasteur

CDIBP

Pneumococcal Vaccine Segment by Type

PPSV 23

PCV 7/13

PCV 10

Pneumococcal Vaccine Segment by End User

Child

Adult

Pneumococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Vaccine Industry Trends Table 2. Pneumococcal Vaccine Industry Drivers Table 3. Pneumococcal Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal Vaccine Industry Restraints Table 5. Global Pneumococcal Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pneumococcal Vaccine Sales by Manufacturers (K Doses) & (2021-2026) Table 8. Global Pneumococcal Vaccine Sales Market Share by Manufacturers Table 9. Global Pneumococcal Vaccine Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Pneumococcal Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pneumococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pneumococcal Vaccine Manufacturers, Product Type & Application Table 13. Global Pneumococcal Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PPSV 23 Table 17. Major Manufacturers of PCV 7/13 Table 18. Major Manufacturers of PCV 10 Table 19. Global Pneumococcal Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 21. Global Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 22. Global Pneumococcal Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Pneumococcal Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Pneumococcal Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Doses) Table 25. Global Pneumococcal Vaccine Revenue by Type (2021-2026) & (K Doses) Table 26. Global Pneumococcal Vaccine Revenue by Type (2027-2032) & (K Doses) Table 27. Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Pneumococcal Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Child Table 30. Major Manufacturers of Adult Table 31. Global Pneumococcal Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 32. Global Pneumococcal Vaccine Sales by Application (2021-2026) & (K Doses) Table 33. Global Pneumococcal Vaccine Sales by Application (2027-2032) & (K Doses) Table 34. Global Pneumococcal Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Pneumococcal Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Pneumococcal Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Doses) Table 37. Global Pneumococcal Vaccine Revenue by Application (2021-2026) & (K Doses) Table 38. Global Pneumococcal Vaccine Revenue by Application (2027-2032) & (K Doses) Table 39. Global Pneumococcal Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Pneumococcal Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 42. Global Pneumococcal Vaccine Sales by Region (2021-2026) & (K Doses) Table 43. Global Pneumococcal Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Pneumococcal Vaccine Sales Forecasted by Region (2027-2032) & (K Doses) Table 45. Global Pneumococcal Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 47. North America Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 48. North America Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 49. Europe Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 50. Europe Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 51. Europe Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 52. Asia Pacific Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 53. Asia Pacific Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 54. Asia Pacific Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 55. South America, Middle East and Africa Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 56. South America, Middle East and Africa Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 57. South America, Middle East and Africa Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 58. Global Pneumococcal Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pneumococcal Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Pneumococcal Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Pneumococcal Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Pneumococcal Vaccine Revenue Market Share by Region (2027-2032) Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Pneumococcal Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Pneumococcal Vaccine Product Portfolio Table 67. Pfizer Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Pneumococcal Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. GSK Pneumococcal Vaccine Product Portfolio Table 72. GSK Recent Development Table 73. MSD Company Information Table 74. MSD Business Overview Table 75. MSD Pneumococcal Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. MSD Pneumococcal Vaccine Product Portfolio Table 77. MSD Recent Development Table 78. Sanofipasteur Company Information Table 79. Sanofipasteur Business Overview Table 80. Sanofipasteur Pneumococcal Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Sanofipasteur Pneumococcal Vaccine Product Portfolio Table 82. Sanofipasteur Recent Development Table 83. CDIBP Company Information Table 84. CDIBP Business Overview Table 85. CDIBP Pneumococcal Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. CDIBP Pneumococcal Vaccine Product Portfolio Table 87. CDIBP Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Pneumococcal Vaccine Distributors List Table 91. Pneumococcal Vaccine Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Product Image Figure 2. Global Pneumococcal Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Pneumococcal Vaccine Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Pneumococcal Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PPSV 23 Image Figure 9. PCV 7/13 Image Figure 10. PCV 10 Image Figure 11. Global Pneumococcal Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global Pneumococcal Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pneumococcal Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Pneumococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 15. Global Pneumococcal Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Child Image Figure 18. Adult Image Figure 19. Global Pneumococcal Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 20. Global Pneumococcal Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pneumococcal Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Pneumococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 23. Global Pneumococcal Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pneumococcal Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 26. North America Pneumococcal Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 28. Canada Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 29. Mexico Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 30. Europe Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 31. Europe Pneumococcal Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 33. France Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 34. U.K. Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 35. Italy Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 36. Netherlands Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 37. Asia Pacific Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 38. Asia Pacific Pneumococcal Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 40. Japan Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 41. South Korea Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 42. Southeast Asia Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 43. India Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 44. Australia Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 45. South America, Middle East and Africa Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 46. South America, Middle East and Africa Pneumococcal Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 48. South Africa Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 49. Saudi Arabia Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 50. Turkey Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 51. Argentina Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 52. UAE Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 53. Egypt Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 54. Chile Pneumococcal Vaccine Sales and Growth Rate (2021-2032) & (K Doses) Figure 55. Global Pneumococcal Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Pneumococcal Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Pneumococcal Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Pneumococcal Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • PPSV 23
  • PCV 7/13
  • PCV 10
Applications
  • Child
  • Adult
Companies covered
  • Pfizer
  • GSK
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumococcal Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumococcal Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pneumococcal Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pneumococcal Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pneumococcal Vaccine Market Dynamics
  1. 2.1 Pneumococcal Vaccine Industry Trends
  2. 2.2 Pneumococcal Vaccine Industry Drivers
  3. 2.3 Pneumococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Industry Restraints
3 Pneumococcal Vaccine Market by Manufacturers
  1. 3.1 Global Pneumococcal Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pneumococcal Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pneumococcal Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pneumococcal Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pneumococcal Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Pneumococcal Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumococcal Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumococcal Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumococcal Vaccine Tier 1, Tier 2, and Tier 3
4 Pneumococcal Vaccine Market by Type
  1. 4.1 Pneumococcal Vaccine Type Introduction
  2. 4.1.1 PPSV 23
  3. 4.1.2 PCV 7/13
  4. 4.1.3 PCV 10
  5. 4.2 Global Pneumococcal Vaccine Sales by Type
  6. 4.2.1 Global Pneumococcal Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumococcal Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Pneumococcal Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pneumococcal Vaccine Revenue by Type
  10. 4.3.1 Global Pneumococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumococcal Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2032)
5 Pneumococcal Vaccine Market by Application
  1. 5.1 Pneumococcal Vaccine Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Pneumococcal Vaccine Sales by Application
  5. 5.2.1 Global Pneumococcal Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pneumococcal Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Pneumococcal Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Pneumococcal Vaccine Revenue by Application
  9. 5.3.1 Global Pneumococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pneumococcal Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Pneumococcal Vaccine Revenue Market Share by Application (2021-2032)
6 Global Pneumococcal Vaccine Sales by Region
  1. 6.1 Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Pneumococcal Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pneumococcal Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pneumococcal Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pneumococcal Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pneumococcal Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pneumococcal Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pneumococcal Vaccine Revenue by Region
  1. 7.1 Global Pneumococcal Vaccine Revenue by Region
  2. 7.1.1 Global Pneumococcal Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pneumococcal Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Pneumococcal Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Pneumococcal Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pneumococcal Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pneumococcal Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pneumococcal Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pneumococcal Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pneumococcal Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Pneumococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Pneumococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GSK Pneumococcal Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 MSD
  14. 8.3.1 MSD Company Information
  15. 8.3.2 MSD Business Overview
  16. 8.3.3 MSD Pneumococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 MSD Pneumococcal Vaccine Product Portfolio
  18. 8.3.5 MSD Recent Developments
  19. 8.4 Sanofipasteur
  20. 8.4.1 Sanofipasteur Company Information
  21. 8.4.2 Sanofipasteur Business Overview
  22. 8.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
  24. 8.4.5 Sanofipasteur Recent Developments
  25. 8.5 CDIBP
  26. 8.5.1 CDIBP Company Information
  27. 8.5.2 CDIBP Business Overview
  28. 8.5.3 CDIBP Pneumococcal Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
  30. 8.5.5 CDIBP Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Vaccine Production Mode & Process
  6. 9.2 Pneumococcal Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Vaccine Distributors
  9. 9.2.3 Pneumococcal Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst